Debates & Didactics in Hematology & Oncology Conference Agenda

THURSDAY, JULY 21

Time
Topic
Speaker
7:30 -7:40 AM
Welcome and Day Overview
Genitourinary Cancers
7:40 – 8:05 AM

DEBATE
Neoadjuvant vs Adjuvant treatment in Localized Upper Tract Urothelial Cancer

8:05 – 8:25 AM
What is New in Prostate Cancer Treatment
8:25 – 8:45 AM
Sequencing of Therapies and Novel Agents in Metastatic Renal Cell Cancer
8:45 – 9:05 AM
Management of Rare Genitourinary Cancers (adenoid cystic carcinoma, penile)
9:05 – 9:25 AM
Treatment Updates in Metastatic Urothelial Cancer
9:25 – 9:45 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A
All speakers
9:45 – 10:10 AM
Break
Head and Neck
10:10 – 10:30 AM
Updates on EGFR-targeted Therapies and Immunotherapies in SCCHN
10:30 – 10:55 AM
DEBATE
Proton Therapy is Superior to IMRT in the Definitive Radiation Therapy Setting: Yes vs No
10:55 – 11:15 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A
All speakers
11:15 – 12:00 AM
Lunch
Brain Cancer
12:00 – 12:20 PM
Management of GBM
Shawn Kothari, MD
Lymphomas Part 1
12:20 – 12:45 PM
Best Management of Elderly Patients with HL (and/or NHL)
12:20 – 12:45 PM
DEBATE
R-CHOP vs Pola-R-CHP for Untreated DLBCL
12:45 – 1:10 PM
DEBATE
CAR T vs Auto-transplant for Relapsed DLBCL
1:10 – 1:30 PM
Current Management of Relapsed/Refractory MCL
1:30 – 1:50 PM
Updates in CLL
1:50 – 2:10 PM
Patient-based Panel Discussion with ASH Highlights and Q&A
All speakers
2:10- 2:15 PM
Closing Comments and Adjourn

FRIDAY, JULY 22

Time
Topic
Speaker
7:30 – 7:35 AM
Welcome and Day Overview
Melanoma
7:35 – 7:55 AM
Improving Survival in Metastatic Uveal Melanoma
7:55 – 8:15 AM
Improving Outcomes for PD-1 Resistant Melanoma: What’s On the Horizon?
8:15 – 8:40 AM
DEBATE
Stage II Melanoma: Is Adjuvant Treatment Appropriate? Yes vs No

8:40 – 9:00 AM

Patient-based Panel Discussion with ASCO Highlights and Q&A
8:40 – 9:05 AM
DEBATE
Stage II Melanoma: Is Adjuvant Treatment Appropriate? Yes vs No
8:40 – 9:00 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A

All speakers

9:00 – 9:25 AM
Break
Leukemia
9:25 – 9:45 AM
Maintenance Therapy in AML
9:45 – 10:10 AM
DEBATE
Should We Transplant Relapsed AML/MDS Not in Remission? Yes vs No
10:10 – 10:35 AM
DEBATE
Should CAR T Therapy Replace alloHCT in B-cell ALL?

10:35 – 11:05 AM

Novel Therapies in Myeloproliferative Neoplasms: Ruxolitinib Combinations and Beyond
11:05 – 11:25 AM
Patient-based Panel Discussion with ASH Highlights and Q&A
All speakers
11:15 – 11:35 AM
Patient-based Panel Discussion with ASH Highlights and Q&A
All speakers
11:25 – 12:10 PM
Lunch
Lecture of the Day
12:10 – 12:35 PM
Success of Precision Medicine Q&A moderated by Medical Oncology fellow
Gastrointestinal Cancers
12:35 – 12:55 PM
Updates on Total Neoadjuvant Therapy and Watch & Wait in Rectal Cancer Management
12:55 – 1:15 PM
Sequencing Treatment Options in Hepatocellular Carcinoma
1:15 – 1:40 PM
DEBATE
Circulating Tumor DNA to Guide Adjuvant Therapy in Colorectal Cancer is Ready for Prime Time: Yes vs No
1:40 – 2:00 PM
Management of Relapsed Pancreatic Cancer
2:00 – 2:20 PM
Patient-based Panel Discussion with ASCO Highlights and Q&A
All speakers
2:20 – 2:25 PM
Closing Comments and Adjourn

SATURDAY, JULY 23

Time
Topic
Speaker
8:00 – 8:05 AM
Welcome and Day Overview
Thoracic Cancers
8:05 – 8:25 AM
Updates in Targeted Therapy for Advanced NSCLC
8:25 – 8:45 AM
What is New in Radiotherapy for NSCLC?
8:25 – 8:50 AM
DEBATE
NGS at the Time of Diagnosis for Advanced NSCLC (Tissue AND Plasma vs Tissue OR Plasma)
8:50 – 9:10 AM
Updates in Immunotherapy for Metastatic NSCLC
9:10 – 9:30 AM
Perioperative Immunotherapy in NSCLC
9:30 – 9:50 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A

All speakers

9:50 – 10:10 AM
Break
Gynecologic Cancers
10:10 – 10:30 AM
Emerging Approaches for Recurrent Endometrial Cancer and Advanced Ovarian Cancer
Lymphomas Part 2
10:30 – 10:50 AM
Developments in T-cell Lymphoma
10:50 – 11:10 AM
Best Management of Elderly Patients with HL (and/or NHL)
Lecture of the Day
11:10 – 11:35 AM
Multi-cancer Early Detection Technology Q&A moderated by Medical Oncology fellow
11:35 – 12:20 PM
Lunch
Lecture of the Day
11:40 – 12:05 PM
Multi-cancer Early Detection Technology
Q&A moderated by Medical Oncology fellow
Myeloma
12:20 – 12:40 PM
Evolution of Modern Induction Regimens in Myeloma: What Does the Future Hold?
12:40 – 1:05 PM
DEBATE
IMID or PI-based Salvage for First Relapse Myeloma
1:05 – 1:25 PM
Choice of Treatment for Relapsed t(11;14) Myeloma: BCL2 Inhibitors or Immunotherapy?
1:25 – 1:45 PM
Cellular Therapies vs Bi-specifics for Multiple Myeloma
1:45 – 2:10 PM
DEBATE
Does Precision Medicine have a Role in MM in the Era of Immune Therapies? Yes vs No
2:10 – 2:30 PM
Patient-based Panel Discussion with ASH Highlights and Q&A
All speakers
2:30 – 2:35 PM
Closing Comments and Adjourn

SUNDAY, JULY 24

Time
Topic
Speaker
8:00 – 8:05 AM
Welcome and Day Overview
Breast Cancer
8:05 – 8:25 AM
Neoadjuvant Therapy and LocregionalControl: A Surgeon’s Perspective
8:25 – 8:45 AM
Ultra-Short Radiation for Early-Stage Breast Cancer: Is 5 treatments the new standard?
8:45 – 9:05 AM
Operable HR+/HER2- Breast Cancer: When to Do Less and When To Do More
9:05 – 9:25 AM
Advances in Metastatic Triple Negative Breast Cancer: Immunotherapy, Antibody Drug Conjugates, and Beyond
9:25 – 9:50 AM
DEBATE
Stage I Triple Negative Breast Cancer: Neoadjuvant Therapy? Yes or No
9:50 – 10:10 AM
Patient-based Panel Discussion with ASCO Highlights and Q&A

All speakers

10:10 – 10:15 AM
Closing Comments and Adjourn